Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 471 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR New reports show staff shortages continue to hold back cancer care June 9, 2022 Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer April 27, 2018 Cancer Patients May Soon Be Able to Get an Entire Course... January 21, 2020 Load more HOT NEWS Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and...
